Aloracetam

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.

Aloracetam
Clinical data
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled Not FDA approved
Identifiers
IUPAC name
  • N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H16N2O2
Molar mass208.261 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI
  • InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15) Y
  • Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N Y
  (verify)

See also

References
  1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
  2. George CF (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
  3. Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
  4. Fischer F, Matthisson M, Herrling P (2004). "List of drugs in development for neurodegenerative diseases". Neuro-Degenerative Diseases. 1 (1): 50–70. doi:10.1159/000077879. PMID 16908974.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.